Accu-Check

What Accu-Check does

Accu-Chek is a diabetes care brand operated by Roche Diabetes Care, Inc., a wholly-owned subsidiary of Roche Holding AG, with its U.S. headquarters in Indianapolis. The company manufactures and sells blood glucose monitoring (BGM) systems for individuals with Type 1, Type 2, and gestational diabetes. Its product portfolio centers on three meter platforms — the Guide Me (entry-level, Bluetooth-enabled, $14.99), the Guide (premium, $19.99, with backlit display, strip ejector, and 720-record memory), and the Guide Link (exclusively paired with Medtronic MiniMed 770G/780G insulin pumps) — supported by proprietary test strips (Guide, Aviva Plus, SmartView) requiring a 0.6 µL blood sample with sub-4-second read times, FastClix and Softclix lancing devices, lancets, and control solutions. The platform claims a '10/10 accuracy' standard (95% of results within ±10 mg/dL of lab reference) with 60,000+ test strips quality-checked weekly against a weekly production run of approximately 80 million strips.

The business follows a razor-and-blade model: meters are sold at low cost or distributed free through voucher and prescription-discount programs to drive an installed base that purchases recurring proprietary consumables. Test strips retail at $16.99 per 100-count and are also covered under Medicare Part B (as low as $1.66 for 50 strips), Medicaid, and commercial insurance. Accu-Chek generates revenue through its own eshop with subscription bundles, major pharmacy chains (CVS, Walgreens, Rite Aid), big-box retailers (Target, Walmart, Costco), grocery pharmacies (Kroger, Safeway, Publix, Albertsons), and online marketplaces (Amazon, Instacart). The acquired mySugr mobile app provides Bluetooth-paired logging, pattern dashboards, and HCP report sharing, with integrations into Apple Health and Google Fit. A healthcare-professional channel supports patient recommendations, while a blog, A1C calculator, and patient-assistance tools drive top-of-funnel education.

The company operates within a mature U.S. BGM category increasingly displaced by continuous glucose monitors, with no disclosed standalone revenue, no recent funding activity, and a discontinued legacy Aviva meter indicating portfolio rationalization. Strategic emphasis is on ecosystem integration (Medtronic pumps, mySugr app), multi-channel distribution, and consumables lock-in rather than on AI-driven differentiation or CGM entry.

Name

Accu-Check

Legal name

Roche Diabetes Care, Inc.

Website

https://accu-chek.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Accu-Chek is a Roche Diabetes Care brand that manufactures and sells blood glucose meters, proprietary test strips, lancing devices, and the mySugr mobile app to individuals with diabetes in the United States, monetizing through recurring consumable sales across retail, e-commerce, and insurance channels.

Ownership category

akta.pro rank

Product category

Blood Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Health and Personal Care Retailers (456)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

akta.pro secondary industries

Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Blood glucose monitoring
• Diabetes care products
• Test strips
• Lancing devices
• Diabetes management app

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Blood Glucose Meters: Sale of blood glucose monitoring devices including Guide, Guide Me, and Guide Link meters. These are one-time hardware purchases that create an installed base of users who then purchase consumables (test strips) on an ongoing basis.
2. Test Strips (Consumables): Recurring revenue from proprietary test strips compatible with Accu-Chek meters. Sold individually and in packs, with subscription options for recurring deliveries. Represents the primary recurring revenue stream.
3. Lancing Devices and Lancets: Sale of lancing devices (FastClix, Softclix) and lancets. Lancets are consumable products requiring regular replacement, providing recurring revenue opportunities.
4. Control Solutions: Quality control solutions for verifying meter and test strip accuracy. Consumable product purchased periodically by users.
5. Digital Health App (mySugr): mySugr app provides diabetes management features. The app is free when paired with compatible Accu-Chek devices, potentially monetizing through premium features or data-driven insights.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Accu-Chek manufactures and sells blood glucose monitoring systems for people with diabetes, including the Guide, Guide Me, and Guide Link meters, plus proprietary Guide, Aviva Plus, and SmartView test strips, FastClix and Softclix lancing devices and lancets, and control solutions for accuracy verification. The offering is supported by the mySugr Bluetooth-enabled diabetes management mobile app, a prescription discount and free meter voucher program, and an omnichannel retail presence spanning the Accu-Chek eShop, Amazon, Walmart, Instacart, major pharmacy chains, big-box retailers, and grocery pharmacies.

Product overview

Accu-Chek is a diabetes care brand owned by Roche Diabetes Care, offering a comprehensive portfolio of blood glucose monitoring products and digital health solutions. The product ecosystem centers on four main blood glucose meter platforms (Guide Me, Guide, Guide Link, and legacy Aviva), each requiring compatible test strips and supported by lancing devices (FastClix and Softclix lines) with corresponding lancets. Control solutions enable quality verification across all systems. The Guide platform represents the most advanced offering with 10/10 accuracy claims, while the Guide Link specifically integrates with Medtronic MiniMed insulin pumps. Digital capabilities are provided through the mySugr mobile app, which connects via Bluetooth to Guide-series meters and integrates with Apple Health and Google Fit. Supporting paper-based tracking is available through the Daily Self-Test Diabetes Diary. Products are available for purchase online via the Accu-Chek eShop and at major retail locations nationwide.

Differentiator

Problem solved

Functional benefit

Brands

• mySugr: A diabetes management mobile application that allows users to log blood glucose levels, meals, and insulin, with Bluetooth connectivity to Accu-Chek Guide meters for automatic data transfer.

Products and services

• Accu-Chek Guide Me Meter A connected blood glucose meter with an easy-fill test strip, fast results in less than 4 seconds, advanced 10/10 accuracy, an easy-to-read LCD screen, and Bluetooth connectivity for mySugr app integration; designed for people with diabetes who want a simple, connected fingerstick monitor.
• Accu-Chek Guide Meter A premium blood glucose meter featuring a strip port light, backlit display, and strip ejector for easier handling, with advanced 10/10 accuracy, 720 diary records, and 32 control results in memory; for people with diabetes who want enhanced usability.
• Accu-Chek Guide Link Meter A companion blood glucose meter exclusively designed to integrate with Medtronic MiniMed 770G and 780G hybrid insulin pumps, with strip port light, backlit display, strip ejector, and 10/10 accuracy; for insulin pump users who want unified sugar-level and insulin-delivery data.
• Accu-Chek Aviva Meter (Discontinued) A now-discontinued legacy blood glucose meter with infrared data transfer, 5-second test time, 15/15 accuracy, and a 500-result memory; listed on the website only to support existing Aviva-system users.
• Accu-Chek Guide Test Strips Easy-fill test strips compatible with Accu-Chek Guide, Guide Me, and Guide Link meters, using a spill-resistant SmartPack vial that allows users to take one strip without spilling others; requires only 0.6 µL of blood.
• Accu-Chek Aviva Plus Test Strips Test strips compatible with the legacy Accu-Chek Aviva-family meters (Aviva, Combo, Connect, Expert, Insight, Nano), featuring an easy-fill tip, 0.6 µL sample, 5-second read time, 15/15 accuracy, and a 20–600 mg/dL measurement range.
• Accu-Chek SmartView Test Strips Test strips compatible with the Accu-Chek Nano meter, designed for easy handling across user ages, with a 5-second read time and 15/20 accuracy, operating between 57°F and 104°F at 10–80% relative humidity.
• Accu-Chek FastClix Lancing Device A lancing device featuring pre-loaded 6-lancet drums that eliminate individual lancet handling, 11 customizable depth settings (0.7–2.2 mm penetration), 30-gauge beveled lancets, Precision Clixmotion technology designed to reduce pain, and a built-in lancet counter.
• Accu-Chek FastClix Lancets Thin-gauge, bevel-cut lancets pre-loaded in 17 drums (102 lancets total) for use exclusively with the Accu-Chek FastClix lancing device, using Precision Clixmotion technology designed to reduce pain and provide smoother entry.
• Accu-Chek Softclix Lancing Device A lancing device designed for comfort, with 11 customizable depth settings (0.8–2.23 mm), Precision Clixmotion technology, one-handed operation, a metal clip for easy storage, and use of 28-gauge bevel-cut lancets.
• Accu-Chek Softclix Lancets Lancets for exclusive use with the Accu-Chek Softclix lancing device, featuring Precision Clixmotion technology designed to reduce pain, sold in 100-lancet packs.
• Accu-Chek Guide Control Solution A control solution used to verify that Accu-Chek Guide, Guide Me, and Guide Link meters and test strips are working properly, stable for 24 months unopened and 3 months after opening.
• Accu-Chek Aviva Control Solution A control solution used to perform control tests on Accu-Chek Aviva systems with Aviva test strips, valid for 3 months after opening or until the printed use-by date.
• Accu-Chek SmartView Control Solution A control solution for verifying the Accu-Chek Nano meter and SmartView test strips are working properly, to be discarded 3 months after opening or on the Use By date.
• mySugr App A diabetes management mobile app that pairs via Bluetooth with Accu-Chek Guide and Guide Me meters for automatic blood-glucose data transfer, offering personalized logging, an analytics dashboard for blood-sugar patterns, and shareable reports, with Apple Health and Google Fit integration.
• Accu-Chek Daily Self-Test Diabetes Diary A physical diabetes logbook for recording blood-glucose checks, medications, and meals across breakfast, lunch, dinner, and bedtime, providing 14 weeks of data per book; available in English and Spanish.

Quantifiable outcome

• 10/10 accuracy: 95% of measured glucose results fall within ±10 mg/dL of lab reference value for concentrations <100 mg/dL and within 10% for concentrations ≥100 mg/dL
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• MedtroniccoreTechnology or IntegrationAccu-Chek Guide Link meter is exclusively designed to integrate with Medtronic MiniMed 770G and 780G hybrid insulin pump systems. This integration allows users to see sugar levels and insulin delivery data on their smartphone, creating a connected diabetes management ecosystem combining CGM/pump therapy with traditional blood glucose monitoring.
• mySugrcoreTechnology or IntegrationmySugr is a diabetes management app that integrates with Accu-Chek Guide and Guide Me meters via Bluetooth. The app provides personalized logging, analytics dashboards for identifying blood sugar patterns, and data reports for sharing with healthcare providers and caregivers. Available free when paired with compatible Accu-Chek devices.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medtronic Diabetes: Medtronic is both a strategic partner (Accu-Chek Guide Link is its exclusive meter for MiniMed 770G/780G pumps) and a competitor with its own Guardian CGM and AID systems that could substitute for Accu-Chek over time.
• LifeScan (OneTouch): OneTouch is a long-standing direct competitor to Accu-Chek in consumer blood glucose meters and test strips, serving the same Type 1/Type 2 diabetes patient population with similar OTC and prescription distribution through retail pharmacies.
• ARKRAY USA: ARKRAY produces GLUCOCARD and other BGM systems distributed through pharmacy channels, competing with Accu-Chek on price and retail placement in the US diabetes supplies market.
• Abbott Diabetes Care (FreeStyle): Abbott competes with both Accu-Chek's BGM (FreeStyle Precision/Neo) and increasingly with its installed base via the FreeStyle Libre CGM system, serving the same diabetes patient population with fingerstick and continuous monitoring alternatives.
• Ascensia Diabetes Care (Contour): Ascensia markets the Contour line of blood glucose meters and strips, directly competing with Accu-Chek Guide and Guide Me in retail pharmacy channels and through healthcare professional endorsements.
• Trividia Health (TRUE METRIX): Trividia Health markets TRUE METRIX blood glucose meters and strips, competing directly with Accu-Chek in the value-tier retail pharmacy segment for cost-sensitive diabetes patients.

Emerging players

• Dexcom: Dexcom is the leading CGM player whose G6/G7 systems are steadily displacing fingerstick BGM as standard of care, particularly in Type 1 diabetes. It represents the primary technological substitute for Accu-Chek's recurring strip model.
• Insulet Corporation (Omnipod): Insulet's tubeless Omnipod insulin pump (now with Omnipod 5 AID integration) competes in the same hybrid closed-loop market where Accu-Chek Guide Link operates as a companion meter, representing an adjacent but overlapping care ecosystem.
• Tandem Diabetes Care: Tandem manufactures the t:slim X2 insulin pump with Control-IQ AID technology, competing with Medtronic's pump ecosystem in which Accu-Chek Guide Link is integrated, making it a peer in the connected insulin delivery space.
• AgaMatrix: AgaMatrix designs and manufactures blood glucose meters and strips (including private-label and store-brand products for major retailers), competing with Accu-Chek in the value and retail private-label segments.

Market position

Strengths2 records

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/AccuChek
• Instagraminstagram.com/accuchek
• Xtwitter.com/accuchek
• YouTubeyoutube.com/accuchek
• LinkedInlinkedin.com/company/accu-chek-customer

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accu-Check